NicOx in-licenses AzaSite and BromSite from InSite Vision

2 February 2015

Ophthalmology-focused French biotech firm NicOx (Euronext Paris: COX) has signed a license agreement with USA-based InSite Vision (OTCBB: INSV) for the development, manufacture and commercialization of InSite's innovative ophthalmic therapeutics AzaSite (1% azithromycin), BromSite (0.075% bromfenac) and AzaSite Xtra (2% azithromycin).

All three products are based on InSite's proprietary Durasite drug delivery technology, which is designed to extend the duration of a drug in the eye.

The agreement grants NicOx exclusive rights to all three products in Europe, Middle East and Africa. European Marketing Authorization Applications for AzaSiteand BromSite are expected to be filed by the first quarter of 2016, with the first launch anticipated in late 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK